Company Description
Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases.
Its investigational product is certepetide, which is in Phase 2 clinical studies for the treatment of solid tumors, such as metastatic pancreatic ductal adenocarcinoma, cholangiocarcinoma, appendiceal cancer, and colon cancer and glioblastoma multiforme in combination with range of anti-cancer regimens.
Lisata Therapeutics, Inc. was formerly known as Caladrius Biosciences, Inc. and changed its name to Lisata Therapeutics, Inc. in September 2022.
The company was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey. As of July 21, 2026, Lisata Therapeutics, Inc. operates as a subsidiary of Kuva Labs, Inc.
| Country | United States |
| Founded | 1980 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 21 |
| CEO | David Mazzo |
Contact Details
Address: 110 Allen Road, 2nd Floor Basking Ridge, New Jersey 07920 United States | |
| Phone | 908 842 0100 |
| Website | lisata.com |
Stock Details
| Ticker Symbol | LSTA |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000320017 |
| CUSIP Number | 128058302 |
| ISIN Number | US1280583022 |
| Employer ID | 22-2343568 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. David J. Mazzo B.A. (Hons), B.Sc. (Hons.), M.Sc., Ph.D. | President, Chief Executive Officer and Director |
| James Nisco | Senior Vice President of Finance, Treasurer, CAO and Principal Financial and Accounting Officer |
| Dr. Kristen K. Buck M.D. | Executive Vice President of Research & Development and Chief Medical Officer |
| Tariq Imam | Senior Vice President of Business Development and Operations and General Counsel |
| Gregory S. Berkin | Chief Information and Data Protection Officer |
| John D. Menditto | Vice President of Investor Relations and Corporate Communications |
| Dr. William K. Sietsema Ph.D. | Vice President of Global Regulatory Affairs |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 24, 2026 | 8-K | Current Report |
| Jul 21, 2026 | SC 14D9/A | Filing |
| Jul 17, 2026 | 8-K | Current Report |
| Jul 17, 2026 | SC 14D9/A | Filing |
| Jul 17, 2026 | SC TO-T/A | Filing |
| Jul 13, 2026 | SC 14D9/A | Filing |
| Jul 10, 2026 | SC TO-T/A | Filing |
| Jul 2, 2026 | SC 14D9/A | Filing |
| Jun 10, 2026 | SC 14D9 | Filing |
| Jun 10, 2026 | SC TO-T | Filing |